GBI Biomanufacturing announced today that it expanded its drug product (DP) services to include automated sterile fill and finish capabilities. Plantation, Florida–based GBI says it can support clients from clinical trials to commercial launch, both for drug products and drug substances. All of this can take place at its Florida plant, delivering advanced and flexible…

Ardena announced today that it received full Good Manufacturing Practice (GMP) approval of its expanded nanomedicine facility in Oss, The Netherlands. The approval enables the pharmaceutical CDMO to conduct GMP manufacturing operations for nanomedicines. It follows a €20 million investment in a state-of-the-art 45,000-square-foot facility offering GMP-compliant Grade C and Grade D cleanrooms designed specifically…

Sekisui Diagnostics announced today that its microbial CDMO business completed construction of a £15.7 million ($20.7 million) drug substance manufacturing capacity expansion. The company completed its cGMP capacity expansion at its U.K. site for clinical-grade drug substance manufacturing. Following appropriate licensure, the expansion can enable manufacturing capabilities for common drug types. Those include enzymes, proteins…

Vitrian announced that it closed a $50 million investment into AmplifyBio and its manufacturing enablement center (AMEC) in Ohio. AmplifyBio, a leading advanced therapy CRO and CDMO, offers a full range of drug development and manufacturing services. The investment, which could scale to $65 million, marks a step toward a larger commitment to support biomanufacturing…

Terumo Blood and Cell Technologies (BCT) announced that it plans to expand its offerings to Latin America. The company plans to help bring automated manufacturing to cell and gene therapy companies in Brazil, Colombia and Mexico. With a focus on automation, it makes products that collect, process and separate blood and cells. The company also…

MilliporeSigma, Merck KGaA’s U.S. and Canada Life Science business, announced a $76 million expansion of its ADC manufacturing capabilities and capacity. The company is expanding the capacity at its Bioconjugation Center of Excellence facility in St. Louis. This investment triples existing capacity and enhances the company’s contract development and manufacturing organization (CDMO) offering. MilliporeSigma said…

Samsung Biologics announced a contract manufacturing deal with an unnamed Asia-based pharmaceutical company worth $1.24 billion. According to a news release, it’s the largest contract signed by a single client. Production will take place at Samsung Biologics’ biomanufacturing site in Songdo, South Korea. The contract runs through December 2037. With this agreement, the company’s accumulated…

PharmaLogic announced today that it opened a new radiopharmaceutical production and research facility in Salt Lake City. The new state-of-the-art facility marks “a major step forward” in the CDMO’s mission to deliver diagnostic and therapeutic radiopharmaceuticals to patients across North America, according to a news release. PharmaLogic said it chose to establish the facility in…

Cellular Origins and Fresenius Kabi announced today that they signed a development agreement over cell and gene therapies (CGTs). The agreement leverages both companies’ expertise in CGTs. They aim to digitally and physically integrate Fresenius Kabi’s suite of cell therapy processing technologies with Cellular Origins’ CGT robotic manufacturing platform, Constellation. With this integration, the companies…

MilliporeSigma, the U.S. and Canadian Life Science unit of Merck KGaA (Darmstadt, Germany) announced today that it opened a new $317 million (€290) biosafety testing facility in Rockville, Maryland. The 23,000-square-meter facility houses biosafety testing, analytical development and cell banking manufacturing services. It consolidates labs currently spread across four buildings into one single facility. MilliporeSigma…